Table 1.
Demographic and clinical characteristics of study patients
| Numbera | Overall | Recurrent | De novo | |
|---|---|---|---|---|
| Demographic characteristics | ||||
| Age, n (%) | 210 | |||
| < 65 years | 99 (47.1%) | 22 (47.8%) | 77 (47.0%) | |
| 65–69 years | 58 (27.6%) | 8 (17.4%) | 50 (30.5%) | |
| ≥ 70 years | 53 (25.2%) | 16 (34.8%) | 37 (22.6%) | |
| Sex, n (%) | 210 | |||
| Males | 127 (60.5) | 33 (71.7) | 94 (57.3) | |
| Females | 83 (39.5) | 13 (28.3) | 70 (42.7) | |
| Clinical characteristics | ||||
| Weight loss > 10%, n (%) | 208 | 81 (38.9) | 9 (20.5) | 72 (43.9) |
| ECOG PS, n (%) | 182 | |||
| 0–1 | 149 (81.9) | 28 (77.8) | 121 (82.9) | |
| 2–3 | 33 (18.1) | 8 (22.2) | 25 (17.1) | |
| Karnofsky PS, n (%) | 55 | |||
| < 70 | 3 (5.5) | – | 3 (6.8) | |
| 70–80 | 33 (60.0) | 7 (63.6%) | 26 (59.1%) | |
| 90–100 | 19 (34.5) | 4 (36.4%) | 15 (34.1%) | |
| Common comorbidities, n (%) | 210 | |||
| Hypertension | 56 (26.7) | 8 (17.4) | 48 (29.3) | |
| Diabetes | 26 (12.4) | 4 (8.7) | 22 (13.4) | |
| Dyslipemia | 29 (13.8) | 6 (13.0) | 22 (13.4) | |
| Hepatobiliary stent, n (%) | 209 | 38 (18.2) | 3 (6.5) | 35 (21.5) |
| Platelet count, median (IR) | 178 | 231.0 (172.0, 318.0) | 207.0 (170.0, 303.0) | 237.0 (181.0, 318.0) |
| Bilirubin (mg/dL), median (IR) | 175 | 0.70 (0.50, 1.00) | 0.57 (0.50, 0.80) | 0.79 (0.50, 1.10) |
| NLR, n (%) | 170 | |||
| > 3 | 91 (53.5) | 18 (52.9) | 73 (53.7) | |
| ≤ 3 | 79 (46.5) | 16 (47.1) | 63 (46.3) | |
| CA 19.9, n (%) | 173 | |||
| > 37 U/mL | 142 (82.1) | 32 (82.1) | 110 (82.1) | |
| ≤ 37 U/mL | 31 (17.9) | 7 (17.9) | 24 (17.9) | |
| Number of metastatic sites, n (%) | 210 | |||
| 1–3 | 205 (97.6) | 46 (100.0) | 159 (97.0) | |
| > 3 | 5 (2.4) | 5 (3.0) | ||
| Concommitant treatment, n (%) | 210 | |||
| Analgesics | 76 (36.2) | 12 (26.1) | 63 (38.4) | |
| Corticosteroids | 25 (11.9) | 4 (8.7) | 20 (12.2) | |
IR Interquartile range (percentile 25, percentile 75)
anumber of evaluable patients (no-missing)